证券代码：300143 证券简称：盈康生命 公告编号：2025-043 盈康生命科技股份有限公司 第六届董事会第二十一次（临时）会议决议公告 1 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 盈康生命科技股份有限公司（以下简称"公司"）于 2025 年 10 月 24 日以电话、 邮件等方式向全体董事发出召开公司第六届董事会第二十一次（临时）会议的通知。 会议于 2025 年 10 月 27 日在山东省青岛市崂山区海尔路一号盈康一生大厦董事会议 室以现场结合通讯的方式召开。会议应出席董事 9 人，实际出席董事 9 人，董事谭 丽霞、马安捷以现场方式出席会议并投票表决，董事黄雯瑶、龚雯雯、潘绵顺、沈 旭东、独立董事杜媛、独立董事姜峰、独立董事陈晓满以通讯方式出席会议并投票 表决。本次会议由董事长谭丽霞女士主持，公司的高级管理人员列席了会议。 本次会议的通知、召集、召开和表决程序符合《中华人民共和国公司法》《公 司章程》及有关法律、法规的规定。 二、董事会会议审议情况 （一）审议通过《关于公司 2025 年第三季度报告的议案》 董事会审议 ...

Revenue and Profitability - The company's revenue for Q3 2025 reached ¥514,808,385, representing a 27.27% increase compared to ¥404,486,660 in the same period last year[4]. - Net profit attributable to shareholders was ¥25,011,711, a decrease of 9.85% from ¥27,743,511 in the previous year[4]. - Basic earnings per share decreased by 23.29% to ¥0.0336 from ¥0.0438 in the same period last year[5]. - Total operating revenue for the current period reached ¥1,357,762,551.29, an increase of 10.6% compared to ¥1,227,709,136.74 in the previous period[29]. - Net profit for the current period was ¥93,807,045.54, representing a 12.5% increase from ¥83,199,781.04 in the previous period[30]. - Earnings per share (EPS) for the current period was ¥0.1168, compared to ¥0.1298 in the previous period, indicating a decrease of 8.2%[31]. - The total comprehensive income for the current period was ¥93,895,819.28, compared to ¥83,135,409.36 in the previous period, indicating a growth of 12.5%[31]. Assets and Liabilities - Total assets increased by 20.37% to ¥4,257,327,588.46 from ¥3,536,733,888.57 at the end of the previous year[5]. - The company reported a total asset of CNY 4,257,327,588.46 as of September 30, 2025, an increase from CNY 3,536,733,888.57 at the beginning of the period[25]. - The company’s total liabilities amounted to CNY 1,835,286,010.02, up from CNY 1,774,670,349.86, reflecting an increase of about 3.2%[26]. - Total liabilities increased to ¥1,640,439,218.11 from ¥1,058,411,535.22, marking a rise of 55%[27]. - Current liabilities due within one year increased by 179.11% to ¥71,898,137.89, primarily due to the leasing of the Guangci Phase II building[12]. - Long-term borrowings rose by 205.44% to ¥466,107,484.50, mainly attributed to increased acquisition loans[12]. Cash Flow and Investments - The company’s cash flow from operating activities showed a slight increase of 0.33% to ¥247,729,500 from ¥246,904,100[5]. - Cash generated from operating activities was ¥1,404,151,215.96, compared to ¥1,281,039,988.86 in the previous period, reflecting a growth of 9.6%[32]. - Total cash inflow from investment activities was $522.90 million, significantly higher than $275.19 million in the prior period, representing an increase of 90.00%[33]. - Cash outflow from investment activities totaled $1.12 billion, up from $699.19 million, indicating a rise of 60.00%[33]. - Net cash flow from financing activities was $184.85 million, compared to $58.36 million in the previous period, showing an increase of 216.00%[33]. - Cash received from investments was $522.81 million, a notable increase from $271.99 million, representing a growth of 92.00%[33]. Equity and Shareholder Information - The company’s total equity attributable to shareholders rose by 3.87% to ¥2,524,691,985.61 from ¥2,430,580,107.07[5]. - Minority interests increased by 93.11% to ¥92,196,384.74, primarily due to the consolidation of Changsha Kexin[12]. - The company had a total of 19,839 common shareholders at the end of the reporting period[14]. - The largest shareholder, Qingdao Yinkang Medical Investment Co., Ltd., holds 49.61% of the shares, totaling 371,782,549 shares[14]. Expenses and Taxation - Total operating costs amounted to ¥1,224,176,374.67, up from ¥1,121,158,642.67, reflecting a growth of 9.2%[29]. - Total tax and additional charges increased by 44.63% to ¥3,934,951.01, primarily due to higher stamp duty and property tax[12]. - Financial expenses rose by 85.13% to ¥4,822,293.98, mainly due to increased long-term borrowings[12]. - Research and development expenses for the current period were ¥32,062,692.84, a decrease of 13% from ¥36,844,629.34 in the previous period[30]. Goodwill and Other Assets - Goodwill increased by 45.91% to ¥1,011,564,085.90 due to the acquisition of Changsha Kexin[11]. - The company’s goodwill rose significantly to CNY 1,011,564,085.90 from CNY 693,292,987.91, indicating an increase of about 45.8%[26]. - The company experienced a 201.83% increase in other receivables, reaching ¥117,456,775.68 from ¥38,914,515.15[11]. Financial Condition and Future Outlook - The company’s financial condition is expected to improve following the approval of the plan to use surplus reserves to cover losses, which is aimed at enhancing investor returns and protecting the rights of minority shareholders[19]. - The company plans to use CNY 1,457,808,920.00 from its surplus reserves and capital reserves to offset accumulated losses, which will reduce surplus reserves to CNY 0[20][21].

Core Insights - The "Mushroom Power Planet" agricultural product promotion event in Shaoguan successfully integrated local culture and tourism, attracting nearly 10,000 participants offline and generating over 50 million online exposures [1][2][4] - The event utilized a live-streaming sales model, significantly enhancing consumer engagement and driving sales through platforms like TVB, which attracted nearly 3 million online viewers [2][3] - The launch of the "Shaozhou Good Scenery" platform aims to create a sustainable online sales channel for local products, promoting year-round purchasing habits among consumers [3][4] Group 1 - The event showcased over 60% of Guangdong's edible mushroom production, emphasizing the region's agricultural strength [1] - The integration of local cultural elements, such as Cantonese food discussions and traditional performances, enhanced audience interaction and experience [2][3] - The event's innovative approach transformed traditional agricultural marketing by creating immersive experiences that combined food tasting, cultural performances, and direct interaction with celebrities [3] Group 2 - The collaboration with Hong Kong TVB for live streaming significantly amplified the event's reach and sales impact, demonstrating the effectiveness of media partnerships in agricultural promotion [2][3] - The event highlighted the modernized industrial chain of Shaoguan's edible mushroom sector, showcasing advancements from research to production [3] - The focus on agricultural and cultural integration not only boosted local product visibility but also stimulated the tourism market, positioning Shaoguan's regional brands prominently [4]

Core Viewpoint - Yingkang Life (300143) reported that as of September 30, 2025, the total number of shareholders is 19,839 [1] Summary by Category - **Company Information** - Yingkang Life has a total of 19,839 shareholders as of the specified date [1]

Core Viewpoint - Yingkang Life's stock price increased by 1.78% on September 30, with a trading volume of 124 million yuan, indicating positive market sentiment towards the company [1]. Financing Summary - On September 30, Yingkang Life had a financing buy-in amount of 13.63 million yuan and a financing repayment of 27.28 million yuan, resulting in a net financing outflow of 13.65 million yuan [1]. - As of September 30, the total financing and securities lending balance for Yingkang Life was 269 million yuan, which accounts for 3.67% of its market capitalization, indicating a high level of financing activity compared to the past year [1]. - The company had a securities lending repayment of 16,800 shares and a securities lending sell-out of 200 shares, with a sell-out amount of 2,284 yuan, reflecting low securities lending activity [1]. Company Overview - Yingkang Life Technology Co., Ltd. is located in Qingdao, Shandong Province, and was established on August 6, 1998, with its listing date on December 9, 2010 [2]. - The company's main business involves medical devices and medical services, with a focus on developing, producing, and selling advanced radiation therapy equipment and establishing a specialized cancer treatment service network [2]. - The revenue composition of Yingkang Life includes 77.47% from medical services and 22.53% from medical devices and consumables [2]. Financial Performance - For the first half of 2025, Yingkang Life reported a revenue of 843 million yuan, representing a year-on-year growth of 2.40%, and a net profit attributable to shareholders of 61.83 million yuan, which is a 12.82% increase compared to the previous year [2]. Dividend Information - Since its A-share listing, Yingkang Life has distributed a total of 29.48 million yuan in dividends, with no dividends paid in the last three years [3].

Group 1 - The core viewpoint of the news is that Yingkang Life has shown a positive stock performance with a year-to-date increase of 24.46% and a recent price of 11.45 CNY per share, despite some fluctuations in trading volume and net capital outflow [1] - As of September 19, the number of shareholders for Yingkang Life decreased by 16.28% to 20,500, while the average circulating shares per person increased by 19.45% to 31,286 shares [2] - The company reported a revenue of 843 million CNY for the first half of 2025, reflecting a year-on-year growth of 2.40%, and a net profit attributable to shareholders of 61.83 million CNY, which is a 12.82% increase year-on-year [2] Group 2 - Yingkang Life specializes in medical devices and services, focusing on cancer prevention, diagnosis, treatment, and rehabilitation, with a revenue composition of 77.47% from medical services and 22.53% from medical devices and consumables [2] - The company has cumulatively distributed 29.48 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3]

Core Viewpoint - The company, Yingkang Life, emphasizes its commitment to clinical value and long-term strategy in the fields of brain-computer interfaces and rehabilitation robotics, focusing on technological maturity and business synergy in its clinical explorations and collaborations [1] Group 1: Strategic Focus - The company is strategically focused on the entire industry chain of tumor pre-diagnosis and treatment, consistently communicating this strategy through regular reports, announcements, and investor engagement activities [1] - The management plans to leverage resources from the Haier ecosystem to steadily enhance core capabilities and actively seek frontier collaboration opportunities that align with its strategy [1] Group 2: Operational Approach - The company prioritizes the maturity of technology and commercial viability in its innovation efforts, reflecting the high technical barriers and stringent regulatory requirements of the medical industry [1] - The management will continue to optimize team structure and attract professional talent to drive high-quality development [1] Group 3: Market Outlook - The company expresses strong confidence in the long-term prospects of the health industry and aims to reward investors' trust through solid operational performance [1]

Core Viewpoint - The company emphasizes the importance of fair and compliant information disclosure, ensuring that all significant information is disclosed in accordance with regulations [1] Group 1: Company Operations - The company reports that its operations are normal and that various strategies are being steadily advanced [1] - There are no significant undisclosed matters that should have been disclosed [1] Group 2: Information Disclosure - The company is committed to optimizing the content and format of its disclosures to ensure timeliness and transparency [1] - The company will actively use diverse channels to communicate its value to the market [1] Group 3: Business Focus - The company remains focused on its core business and is dedicated to achieving high-quality development [1]

Core Viewpoint - The company emphasizes its commitment to clinical value and long-term strategy in cutting-edge fields such as brain-computer interfaces and rehabilitation robots, focusing on the maturity of technology and commercial viability [1] Group 1: Strategic Focus - The company is advancing clinical explorations and collaborations based on the maturity of technology and business synergy, given the high technical barriers and strict regulatory requirements in the medical industry [1] - The company aims to continuously communicate its strategic path focused on the entire industry chain of tumor pre-diagnosis and treatment through regular reports, announcements, and investor engagement activities [1] Group 2: Future Plans - The company plans to leverage resources from the Haier ecosystem to steadily enhance its core capabilities while actively seeking frontier collaboration opportunities that align with its strategy [1] - Management will continue to optimize team structure and broadly recruit professional talent to drive high-quality development of the company [1]

Core Viewpoint - The company emphasizes the importance of internal governance and compliance in its operations, focusing on building a robust ethical framework to prevent unethical business practices [1] Group 1: Internal Governance - The company is committed to strengthening its institutional framework to enhance internal governance and compliance [1] - It has established a comprehensive integrity management system to effectively supervise and prevent corruption and unfair competition [1] Group 2: Ethical Standards - The company strictly adheres to its Business Code of Conduct and Supplier Code of Conduct, which outline clear ethical guidelines for its operations and partnerships [1] - It aims to set a clear moral baseline for both the company and its partners through these codes [1] Group 3: Employee Management - The company enhances ethical awareness and management among its internal employees through dedicated training and initiatives [1] - It has implemented corresponding supervision and auditing mechanisms to ensure fairness and transparency in its business activities [1]